{"transactions":[{"id":677217,"issuer":{"id":7081,"kind":"organization","name":"Odysight.ai Inc."},"owners":[{"id":20291,"kind":"person","name":"Arkin Moshe","position":1,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-24T20:05:16.000Z","date":"2026-08-20","kind":"purchase","planned":false,"acquired":true,"shares":1125000,"price":3.2,"value":3600000.0,"ownership":{"direct":false,"nature":"Held through M.Arkin (1999) Ltd."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On August 20, 2026, the Reporting Person acquired 1,125,000 shares of common stock in the Issuer's underwritten public offering of shares of common stock for an offering price of $3.20 per share of common stock."}],"balance_after":4084143,"source":{"system":"sec-edgar","filing":"0001493152-26-039861","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1321178/000149315226039861/ownership.xml","form_type":"4"}},{"id":826197,"issuer":{"id":7081,"kind":"organization","name":"Odysight.ai Inc."},"owners":[{"id":20291,"kind":"person","name":"Arkin Moshe","position":1,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants to purchase common stock","published_at":"2026-03-27T20:05:08.000Z","date":"2026-03-25","kind":"exercise","planned":false,"acquired":true,"shares":2352941,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held through Phoenix Insurance Company Ltd."},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The cashless exercise of the warrant to purchase common stock was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors."}],"balance_after":0,"derivative":{"exercise_price":5.5,"exercise_date":"2023-03-27","expiration_date":"2026-03-26","underlying":"Common Stock","underlying_shares":2352941},"source":{"system":"sec-edgar","filing":"0001493152-26-013193","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1321178/000149315226013193/ownership.xml","form_type":"4"}},{"id":826196,"issuer":{"id":7081,"kind":"organization","name":"Odysight.ai Inc."},"owners":[{"id":20291,"kind":"person","name":"Arkin Moshe","position":1,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-27T20:05:08.000Z","date":"2026-03-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":2081044,"price":5.5,"value":11445742.0,"ownership":{"direct":false,"nature":"Held through Phoenix Insurance Company Ltd."},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"On March 25, 2026, Phoenix Insurance Company Ltd. exercised a warrant to purchase 2,352,941 shares of the Issuer's common stock for $5.50 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in the Issuer withholding 2,081,044 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 271,897 shares."}],"balance_after":2624838,"source":{"system":"sec-edgar","filing":"0001493152-26-013193","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1321178/000149315226013193/ownership.xml","form_type":"4"}},{"id":826195,"issuer":{"id":7081,"kind":"organization","name":"Odysight.ai Inc."},"owners":[{"id":20291,"kind":"person","name":"Arkin Moshe","position":1,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-27T20:05:08.000Z","date":"2026-03-25","kind":"exercise","planned":false,"acquired":true,"shares":2352941,"price":5.5,"value":12941175.5,"ownership":{"direct":false,"nature":"Held through Phoenix Insurance Company Ltd."},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The cashless exercise of the warrant to purchase common stock was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Board of Directors."},{"field":"shares","element":"transactionShares","label":"F2","text":"On March 25, 2026, Phoenix Insurance Company Ltd. exercised a warrant to purchase 2,352,941 shares of the Issuer's common stock for $5.50 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in the Issuer withholding 2,081,044 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 271,897 shares."}],"balance_after":4705882,"source":{"system":"sec-edgar","filing":"0001493152-26-013193","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1321178/000149315226013193/ownership.xml","form_type":"4"}},{"id":2729684,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":139745,"kind":"organization","name":"Arkin Bio Ventures 2 L.P.","position":1,"cik":"0001858705","reported_name":"Arkin Bio Ventures 2 L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139746,"kind":"organization","name":"Arkin Bio Ventures GPGP Ltd.","position":2,"cik":"0001858707","reported_name":"Arkin Bio Ventures GPGP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20291,"kind":"person","name":"Arkin Moshe","position":3,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-05-04T20:31:02.000Z","date":"2021-05-04","kind":"exercise","acquired":false,"shares":3560551,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Arkin Bio Ventures 2 L.P. (the \"Fund\"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":410717},"source":{"system":"sec-edgar","filing":"0000899243-21-018121","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1321178/000089924321018121/doc4.xml","form_type":"4"}},{"id":2729683,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":139745,"kind":"organization","name":"Arkin Bio Ventures 2 L.P.","position":1,"cik":"0001858705","reported_name":"Arkin Bio Ventures 2 L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139746,"kind":"organization","name":"Arkin Bio Ventures GPGP Ltd.","position":2,"cik":"0001858707","reported_name":"Arkin Bio Ventures GPGP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20291,"kind":"person","name":"Arkin Moshe","position":3,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-05-04T20:31:02.000Z","date":"2021-05-04","kind":"exercise","acquired":false,"shares":10714284,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Arkin Bio Ventures 2 L.P. (the \"Fund\"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1235917},"source":{"system":"sec-edgar","filing":"0000899243-21-018121","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1321178/000089924321018121/doc4.xml","form_type":"4"}},{"id":2729682,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":139745,"kind":"organization","name":"Arkin Bio Ventures 2 L.P.","position":1,"cik":"0001858705","reported_name":"Arkin Bio Ventures 2 L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139746,"kind":"organization","name":"Arkin Bio Ventures GPGP Ltd.","position":2,"cik":"0001858707","reported_name":"Arkin Bio Ventures GPGP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20291,"kind":"person","name":"Arkin Moshe","position":3,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T20:31:02.000Z","date":"2021-05-04","kind":"purchase","acquired":true,"shares":400000,"price":16,"value":6400000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Arkin Bio Ventures 2 L.P. (the \"Fund\"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund."}],"balance_after":2046634,"source":{"system":"sec-edgar","filing":"0000899243-21-018121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1321178/000089924321018121/doc4.xml","form_type":"4"}},{"id":2729681,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":139745,"kind":"organization","name":"Arkin Bio Ventures 2 L.P.","position":1,"cik":"0001858705","reported_name":"Arkin Bio Ventures 2 L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139746,"kind":"organization","name":"Arkin Bio Ventures GPGP Ltd.","position":2,"cik":"0001858707","reported_name":"Arkin Bio Ventures GPGP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20291,"kind":"person","name":"Arkin Moshe","position":3,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T20:31:02.000Z","date":"2021-05-04","kind":"exercise","acquired":true,"shares":410717,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Arkin Bio Ventures 2 L.P. (the \"Fund\"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund."}],"balance_after":1646634,"source":{"system":"sec-edgar","filing":"0000899243-21-018121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1321178/000089924321018121/doc4.xml","form_type":"4"}},{"id":2729680,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":139745,"kind":"organization","name":"Arkin Bio Ventures 2 L.P.","position":1,"cik":"0001858705","reported_name":"Arkin Bio Ventures 2 L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":139746,"kind":"organization","name":"Arkin Bio Ventures GPGP Ltd.","position":2,"cik":"0001858707","reported_name":"Arkin Bio Ventures GPGP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20291,"kind":"person","name":"Arkin Moshe","position":3,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T20:31:02.000Z","date":"2021-05-04","kind":"exercise","acquired":true,"shares":1235917,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held by Arkin Bio Ventures 2 L.P. (the \"Fund\"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund."}],"balance_after":1235917,"source":{"system":"sec-edgar","filing":"0000899243-21-018121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1321178/000089924321018121/doc4.xml","form_type":"4"}},{"id":3178067,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":149884,"kind":"organization","name":"Arkin Bio Ventures Limited Partnership","position":1,"cik":"0001808348","reported_name":"Arkin Bio Ventures Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149885,"kind":"organization","name":"Arkin Bio Venture Partners Ltd.","position":2,"cik":"0001808349","reported_name":"Arkin Bio Venture Partners Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20291,"kind":"person","name":"Arkin Moshe","position":3,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Preferred Stock","published_at":"2020-04-13T17:29:33.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":167537,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are held by Arkin Bio Ventures Limited Partnership (\"Arkin Bio\"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":167537},"source":{"system":"sec-edgar","filing":"0001178913-20-001105","document":"zk2024260.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1808348/000117891320001105/zk2024260.xml","form_type":"4"}},{"id":3178066,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":149884,"kind":"organization","name":"Arkin Bio Ventures Limited Partnership","position":1,"cik":"0001808348","reported_name":"Arkin Bio Ventures Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149885,"kind":"organization","name":"Arkin Bio Venture Partners Ltd.","position":2,"cik":"0001808349","reported_name":"Arkin Bio Venture Partners Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20291,"kind":"person","name":"Arkin Moshe","position":3,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Preferred Stock","published_at":"2020-04-13T17:29:33.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":343270,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are held by Arkin Bio Ventures Limited Partnership (\"Arkin Bio\"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":343270},"source":{"system":"sec-edgar","filing":"0001178913-20-001105","document":"zk2024260.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808348/000117891320001105/zk2024260.xml","form_type":"4"}},{"id":3178065,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":149884,"kind":"organization","name":"Arkin Bio Ventures Limited Partnership","position":1,"cik":"0001808348","reported_name":"Arkin Bio Ventures Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149885,"kind":"organization","name":"Arkin Bio Venture Partners Ltd.","position":2,"cik":"0001808349","reported_name":"Arkin Bio Venture Partners Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20291,"kind":"person","name":"Arkin Moshe","position":3,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-04-13T17:29:33.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":1382295,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are held by Arkin Bio Ventures Limited Partnership (\"Arkin Bio\"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1382295},"source":{"system":"sec-edgar","filing":"0001178913-20-001105","document":"zk2024260.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808348/000117891320001105/zk2024260.xml","form_type":"4"}},{"id":3178064,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":149884,"kind":"organization","name":"Arkin Bio Ventures Limited Partnership","position":1,"cik":"0001808348","reported_name":"Arkin Bio Ventures Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149885,"kind":"organization","name":"Arkin Bio Venture Partners Ltd.","position":2,"cik":"0001808349","reported_name":"Arkin Bio Venture Partners Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20291,"kind":"person","name":"Arkin Moshe","position":3,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T17:29:33.000Z","date":"2020-04-13","kind":"purchase","acquired":true,"shares":120000,"price":16,"value":1920000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are held by Arkin Bio Ventures Limited Partnership (\"Arkin Bio\"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.."}],"balance_after":2013102,"source":{"system":"sec-edgar","filing":"0001178913-20-001105","document":"zk2024260.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808348/000117891320001105/zk2024260.xml","form_type":"4"}},{"id":3178063,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":149884,"kind":"organization","name":"Arkin Bio Ventures Limited Partnership","position":1,"cik":"0001808348","reported_name":"Arkin Bio Ventures Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149885,"kind":"organization","name":"Arkin Bio Venture Partners Ltd.","position":2,"cik":"0001808349","reported_name":"Arkin Bio Venture Partners Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20291,"kind":"person","name":"Arkin Moshe","position":3,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T17:29:33.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":167537,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are held by Arkin Bio Ventures Limited Partnership (\"Arkin Bio\"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.."}],"balance_after":1893102,"source":{"system":"sec-edgar","filing":"0001178913-20-001105","document":"zk2024260.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808348/000117891320001105/zk2024260.xml","form_type":"4"}},{"id":3178062,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":149884,"kind":"organization","name":"Arkin Bio Ventures Limited Partnership","position":1,"cik":"0001808348","reported_name":"Arkin Bio Ventures Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149885,"kind":"organization","name":"Arkin Bio Venture Partners Ltd.","position":2,"cik":"0001808349","reported_name":"Arkin Bio Venture Partners Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20291,"kind":"person","name":"Arkin Moshe","position":3,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T17:29:33.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":343270,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are held by Arkin Bio Ventures Limited Partnership (\"Arkin Bio\"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.."}],"balance_after":1725565,"source":{"system":"sec-edgar","filing":"0001178913-20-001105","document":"zk2024260.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808348/000117891320001105/zk2024260.xml","form_type":"4"}},{"id":3178061,"issuer":{"id":6242,"kind":"organization","name":"Keros Therapeutics, Inc."},"owners":[{"id":149884,"kind":"organization","name":"Arkin Bio Ventures Limited Partnership","position":1,"cik":"0001808348","reported_name":"Arkin Bio Ventures Limited Partnership","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":149885,"kind":"organization","name":"Arkin Bio Venture Partners Ltd.","position":2,"cik":"0001808349","reported_name":"Arkin Bio Venture Partners Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20291,"kind":"person","name":"Arkin Moshe","position":3,"cik":"0001321178","reported_name":"Arkin Moshe","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T17:29:33.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":1382295,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock converted into shares of Common Stock upon the closing of the Issuer's initial public offering, on a one-for-one basis, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities are held by Arkin Bio Ventures Limited Partnership (\"Arkin Bio\"). Arkin Bio Venture Partners Ltd. is the general partner of Arkin Bio. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Venture Partners Ltd.."}],"balance_after":1382295,"source":{"system":"sec-edgar","filing":"0001178913-20-001105","document":"zk2024260.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808348/000117891320001105/zk2024260.xml","form_type":"4"}}]}